Compared with other organs, the brain is highly enriched in cholesterol. Essentially all cholesterol in the brain is synthesized within the brain; the blood-brain barrier prevents the import of plasma lipoproteins into the brain. Consequently, the brain operates an independent lipoprotein transport system in which glial cells produce ApoE (apolipoprotein E)-containing lipoproteins that are thought to deliver cholesterol to neurons for axonal growth and repair. We have shown that ApoE-containing lipoproteins generated by glial cells stimulate axon extension. ApoE associated with lipoprotein particles, and a receptor of the lowdensity lipoprotein receptor family, are required for stimulation of axon growth. NPC (Niemann-Pick type C) disease is a severe neurological disorder caused by mutations in the NPC1 or NPC2 gene. A hallmark of this disease is impaired transport of cholesterol out of late endosomes/lysosomes and the accumulation of cholesterol in these organelles. Although cholesterol accumulates in cell bodies of neurons from NPC1-deficient mice, the cholesterol content of axons is reduced. The presence of NPC1 in endosomal structures in nerve terminals, and the finding of aberrant synaptic vesicles, suggest that defects in synaptic vesicle recycling contribute to neurological abnormalities characteristic of NPC disease. We have also shown that ApoE-containing lipoproteins produced by glial cells from NCP1-deficient mice are of normal composition and stimulate axon extension.
the brain is synthesized within the brain and very little cholesterol is imported into the brain from plasma. Interest in understanding the mechanisms by which cholesterol metabolism in the CNS is regulated has increased recently because defects in cholesterol homoeostasis in the brain have been linked to development of several neurological disorders, including Alzheimer's disease and NPC (Niemann-Pick type C) disease (reviewed in [7] ).
Role of lipoproteins and ApoE (apolipoprotein E) in cholesterol transport in the CNS
Although plasma lipoproteins are not imported into the CNS, experimental evidence suggests that a population of lipoproteins, distinct from those in the plasma, mediates cholesterol transport within cells of the CNS. Many of the molecules [such as ApoE and ApoA1, as well as receptors of the LDL (low-density lipoprotein) receptor superfamily and the ABC transporters (ATP-binding-cassette transporters) ABCA1, ABCG1 and ABCG4] that are involved in cholesterol transport in plasma are relatively abundant in the CNS. Moreover, lipoproteins the size and density of highdensity lipoproteins have been isolated from the CNS [8] [9] [10] . ApoE, the major apolipoprotein in the CNS, plays a central role in cholesterol transport in the nervous system. In the brain, ApoE is synthesized primarily by astrocytes and is a component of lipoproteins that also contain cholesterol and phospholipids [8] [9] [10] . After nerve injury in the central or peripheral nervous systems, the synthesis of ApoE by glial cells increases dramatically (by up to 150-fold) [11] [12] [13] . ApoE-containing lipoproteins secreted by glial cells bind to, and can be taken up by, lipoprotein receptors on neurons [14] and are thought to deliver cholesterol for growth and repair of injured neurons [15] . In support of this idea, we have shown that distal axons of cultured rat sympathetic neurons take up both the lipid and protein components of lipoproteins and transport these molecules into cell bodies [16] . Cholesterol delivered by lipoproteins can be utilized for axon growth [16] . Not only do ApoE-binding receptors participate in cholesterol uptake, but also these receptors are required in neurons for signalling pathways that are particularly crucial during CNS development [17, 18] . In humans, there are three common alleles of ApoE (ApoE2, ApoE3 and ApoE4); inheritance of the ApoE4 allele is the strongest known genetic risk factor for the development of late-onset Alzheimer's disease [19] [20] [21] . These observations, among many others, indicate that ApoE is a key player in cholesterol metabolism in the brain (reviewed in [7] ).
ApoE-containing glial lipoproteins stimulate axon extension of CNS neurons
In neurons, cholesterol is synthesized in cell bodies but not in distal axons [22] , and an efficient anterograde transport process exists for supplying distal axons with endogenously synthesized cholesterol. In contrast, the most abundant membrane lipid, phosphatidylcholine, is synthesized in both cell bodies and axons [22, 23] . Inhibition of cholesterol synthesis in cultured sympathetic neurons reduces the rate of axon extension by approx. 50% [24] , but axon growth can be restored by addition of cholesterol or plasma lipoproteins to either the cell bodies or distal axons [16, 24] .
Since glial lipoproteins are thought to be the physiologically relevant source of ApoE in the CNS, we investigated whether or not ApoE-containing lipoproteins secreted by glial cells increased the rate of axon growth of retinal ganglion cells, a type of CNS neuron. ApoE-containing lipoproteins were isolated from the medium of cultured cortical glial cells (>90% astrocytes) and applied to either distal axons or cell bodies/proximal axons of retinal ganglion neurons. These neurons were cultured in compartmented dishes in which cell bodies and distal axons reside in separate compartments that form distinct fluid environments [25, 26] . When glial lipoproteins were given to distal axons alone, the rate of axonal extension was increased by approx. 50%. In contrast, when glial lipoproteins were applied to cell bodies/proximal axons alone, axonal growth was not increased [26] . ApoE associated with a lipoprotein particle is required for stimulation of growth because lipoproteins secreted by ApoE −/− glia do not enhance axon extension, nor does cholesterol or ApoE alone. A receptor of the LDL receptor family is required for the growth-stimulatory effect since the receptor-associated protein, RAP, blocks the increase in growth [26] . These observations demonstrate that ApoE, present in lipoproteins secreted by astrocytes, stimulates axon extension in a process that involves binding of the lipoprotein to a receptor of the LDL receptor family. These experiments do not, however, distinguish between the growth-stimulatory effect being mediated by cholesterol uptake from lipoprotein particles or by a signalling pathway that is initiated when ApoE-containing lipoproteins bind to the receptor.
Cholesterol metabolism in NPC disease
NPC disease is a severe, progressive neurological disorder characterized by cerebellar ataxia, supranuclear gaze palsy and other neurological impairments, leading to premature death usually in the second decade of life. In 95% of the cases, this disorder is caused by mutations in the NPC1 gene [27, 28] , whereas the remaining 5% of cases result from mutations in the NPC2 gene [29] . NPC disease is characterized by an accumulation of unesterified cholesterol and other lipids in tissues, particularly the liver and spleen but, surprisingly, not in adult brain [30] [31] [32] . The most likely reason why the overall cholesterol content of the brain is not increased is that NPC deficiency causes a loss of myelin that is very rich in cholesterol [33, 34] .
The most obvious biochemical phenotype exhibited by cells lacking functional NPC1 or NPC2 is an accumulation of unesterified cholesterol, gangliosides and lysobisphosphatidic acid within late endosomes/lysosomes. In NPC1-deficient peripheral cells, the primary source of the cholesterol that accumulates is endocytosed LDLs [35, 36] . However, endogenously synthesized cholesterol is also sequestered within the endosomal pathway [37] . A consequence of this blockage in cholesterol trafficking out of the endosomal system is that cholesterol transport to the plasma membrane is diminished by NPC1 deficiency [38] . Moreover, a defect in the movement of unesterifed cholesterol from late endosomes/lysosomes to the endoplasmic reticulum impairs normal cholesterol homoeostatic responses in fibroblasts, resulting in increased cholesterol synthesis, increased expression of LDL receptors and a decreased rate of cholesterol esterification (reviewed in [39, 40] ).
The NPC1 protein is a large (1278 amino acids) late endosomal/lysosomal protein that contains 13 transmembrane domains, five of which are homologous with the sterolsensing domains of other proteins involved in regulating cholesterol metabolism (reviewed in [40] ). In addition, the NPC1 protein encompasses a lysosomal targeting motif and a leucine zipper motif. The NPC2 protein is a small (151 amino acids), soluble, cholesterol-binding protein that is also located in late endosomes/lysosomes [41] [42] [43] . The precise functions of these proteins are not yet known. Nevertheless, the presence of a sterol-sensing domain in NPC1, and the observation that large amounts of unesterified cholesterol accumulate in late endosomes/lysosomes of cells lacking functional NPC1 or NPC2, imply that these proteins are involved in transporting cholesterol out of late endosomes/lysosomes (reviewed in [44, 45] ).
Cholesterol metabolism in NPC1-deficient glial cells
The mechanism by which the accumulation of lipids in late endosomes/lysosomes results in neurological problems characteristic of NPC disease has not yet been elucidated. Despite the cloning of the NPC1 gene in 1997 [27] , and the recognition that defects in the NPC2 gene cause NPC disease [29] , the precise functions of the NPC proteins have not yet been defined. Several important questions remain regarding the cause(s) of the disease pathology. Is the severe neurological phenotype the direct result of excessive storage of cholesterol in late endosomes/lysosomes or, alternatively, are the problems caused by a deficiency of cholesterol at key sites in the cell? Are the neurological problems the result of dysfunctional processes in glial cells or in the neurons? Is a defect in cholesterol trafficking the primary result of NPC deficiency or is the cholesterol accumulation secondary to an impaired trafficking of one of the other lipids, such as gangliosides, that also accumulate? My laboratory has attempted to answer some of these questions by studying NPC1 deficiency in primary cultures of glial cells and neurons isolated from brains of a mouse model of NPC disease [28] . Previously, most studies that investigated NPC function were performed in fibroblasts or Chinese-hamster ovary cell mutants [35, 46] .
Glial cells (primarily astrocytes, oligodendrocytes and microglia) make up approx. 90% of the cells in the human brain. Glial cells interact with neurons and are associated with synaptic transmission and neuronal excitability [47] . All three types of glial cells appear to be affected and accumulate cholesterol in NPC disease [48, 49] . In NPC patients, and in mice lacking NPC1, the cholesterol that accumulates in peripheral tissues appears to be derived from LDLs that are internalized by receptor-mediated endocytosis [50, 51] . However, the brain is unable to import LDLs from the peripheral circulation. Thus most of the cholesterol accumulating in NPC1-deficient neurons and glial cells is synthesized endogenously within the CNS.
Since glial cells are so abundant in the brain and accumulate cholesterol as a result of NPC1 deficiency, we tested the hypothesis that sequestration of cholesterol within glial cells impairs the formation of glial lipoproteins, thereby contributing to the neurological deficits in NPC disease. The secretion of ApoE-containing lipoproteins by glial cells (>95% astrocytes) from the cerebellum of Npc1 +/+ and Npc1 −/− mice was, therefore, examined. Filipin staining revealed that the intracellular distribution of cholesterol in the glial cells was markedly altered by NPC1 deficiency [52] , in a manner similar to that seen in NPC1-deficient fibroblasts. However, neither the cholesterol content nor the ApoE content of glia-conditioned medium was altered by NPC1 deficiency, and the size of lipoprotein particles generated by glial cells of the two genotypes was indistinguishable. In addition, the efflux of cholesterol from glial cells to exogenous acceptor apolipoproteins was not impaired in Npc1 −/− glia. Moreover, the amount of ABCA1, a transporter that determines the amount of cholesterol and phospholipid effluxed to apolipoprotein acceptors, was also not reduced in Npc1 −/− glia compared with Npc1 +/+ glia [52] . Importantly, lipoproteins generated by Npc1 −/− glia stimulated axon extension to the same extent as did Npc1 +/+ glial lipoproteins [52] .
Thus the composition and function of ApoE-containing lipoproteins generated by Npc1 −/− glia appear to be normal by all criteria examined.
NPC1-deficient neurons
NPC1 deficiency in sympathetic neurons [53, 54] , as well as in cerebellar and cortical neurons [55] , significantly alters the distribution of intracellular cholesterol, as shown by the characteristic punctate intracellular staining with filipin. Despite the dramatically different filipin staining pattern in cultured Npc1
−/− and Npc1 +/+ neurons, the total amount of cholesterol was the same [53] . However, upon further investigation, we found that the cholesterol content of cell bodies of the neurons was increased by NPC1 deficiency, whereas the amount of cholesterol in distal axons was reduced, resulting in no overall change in cholesterol content of the neurons. This redistribution of cholesterol in the neurons correlated with a reduced rate of anterograde transport of endogenously synthesized cholesterol from cell bodies into distal axons [54] . Not only was the transport of endogenously made cholesterol inhibited by NPC1 deficiency, but when LDL-derived cholesterol was provided to cell bodies of Npc1 −/− neurons in which cholesterol synthesis had been inhibited, normal axon growth was not restored. These results demonstrate that the lack of functional NPC1 in neurons inhibits cholesterol transport from cell bodies to distal axons, and causes an accumulation of cholesterol in cell bodies and a reduction in the cholesterol content of distal axons. On the basis of these observations, we speculated that in addition to the cholesterol accumulation that occurs in all NPC1-deficient cells, a neuron-specific process in distal axons might be impaired by the reduction in cholesterol content.
The NPC1 and NPC2 proteins have been localized to late endosomes/lysosomes. In neurons, lysosomal degradation is presumed to occur in cell bodies [56, 57] . We were, therefore, surprised to discover that in sympathetic neurons, NPC1 and NPC2 are abundant not only in cell bodies/proximal axons but also in distal axons [54] . Moreover, when Npc1 −/− neurons were infected with adenoviruses containing a cDNA insert encoding NPC1 fused to green fluorescent protein, we observed a bi-directional movement of the fluorescent chimaeric protein between cell bodies and axons [58] . Thus we investigated further the localization and function of NPC1 in distal axons. Some important processes that occur in distal axons are neurotransmitter release and synaptic vesicle recycling. Immunoblotting and immunofluorescence studies revealed that NPC1 is present in synaptosomes derived from mouse cerebellum and that NPC1 extensively co-localizes with synaptophysin, a cholesterol-binding protein that is a marker of synaptic vesicles [59] . Tethering of synaptic vesicles to the plasma membrane depends on the cholesterol content of this membrane [60] . Co-immunoprecipitation of synaptophysin and NPC1 from homogenates of the cerebellum and neurons with anti-synaptophysin antibodies demonstrated that NPC1 and synaptophysin are, at least partially, localized to the same population of vesicles. Further fractionation of synaptosomes showed that purified synaptic vesicles do not contain NPC1. In contrast, NPC1 in nerve terminals co-localizes with the lysosomal/endosomal marker protein LAMP1 (lysosome-associated membrane protein 1), suggesting that in the nerve terminal, NPC1 is present in endosomes, probably the recycling endosomes involved in synaptic vesicle recycling [61] . The protein composition of synaptic vesicles from Npc1 +/+ and Npc1 −/− mice is different; in Npc1 −/− synaptic vesicles, the ratio of VAMP2 (vesicle-associated membrane protein 2) to synaptophysin is lower than that in Npc1 +/+ vesicles. Moreover, the sedimentation behaviour of synaptic vesicles is altered by NPC1 deficiency. However, the cholesterol content of synaptic vesicles from Npc1 +/+ and Npc1 −/− synaptosomes is not significantly different. Electron microscopic studies of synaptosomes isolated from the cerebellum showed that Npc1 −/− synaptosomes contain a population of aberrantly large vesicles that are not present in Npc1 +/+ synaptosomes. This finding was supported by gradient ultracentrifugation experiments in which a population of aberrantly large synaptic vesicles in NPC1-deficient synaptosomes was observed [61] .
These findings provide the basis for a model in which impaired transport of cholesterol from cell bodies to distal axons of neurons, and a defect in the function of NPC1 in recycling endosomes that participate in synaptic vesicle recycling, contribute to the progressive neurodegeneration in NPC disease. From our studies in cultured neurons and glial cells isolated from the mouse model of NPC disease, we speculate that the neurological problems characteristic of NPC disease are caused by defective processes in neurons rather than in glial cells. However, we cannot exclude the possibility that with increasing age of the animal, defects in glial lipoprotein metabolism might become apparent.
